GLP-1 drugs often cause weight loss because they mimic the GLP-1 hormone the body naturally produces after eating. Appetite ...

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

Opening Minds through Art (OMA) is an award-winning, evidence-based program. It’s an opportunity for creative self-expression ...

When people were randomised to receive either a placebo or Ozempic, they became biologically younger with the latter drug ...

The clinical benefits of donanemab (Kisunla) continued over 3 years in people with early symptomatic Alzheimer's disease, ...